Lexeo Therapeutics (NASDAQ:LXEO) Releases Earnings Results, Beats Expectations By $0.04 EPS

Lexeo Therapeutics (NASDAQ:LXEO) posted its quarterly earnings data on Monday. The company reported ($0.25) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.04, FiscalAI reports.

Lexeo Therapeutics Trading Up 3.6%

LXEO traded up $0.21 on Monday, hitting $6.04. The company had a trading volume of 379,835 shares, compared to its average volume of 958,574. The company’s fifty day moving average price is $6.26 and its 200 day moving average price is $7.82. Lexeo Therapeutics has a 1 year low of $2.43 and a 1 year high of $10.99. The firm has a market cap of $474.27 million, a P/E ratio of -2.76 and a beta of 1.52.

Insider Buying and Selling

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $5.69, for a total value of $312,950.00. Following the transaction, the chief executive officer directly owned 340,106 shares in the company, valued at $1,935,203.14. This represents a 13.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 68,189 shares of company stock valued at $397,156 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Institutional Trading of Lexeo Therapeutics

Several hedge funds have recently made changes to their positions in the company. RA Capital Management L.P. purchased a new position in Lexeo Therapeutics during the 4th quarter valued at about $49,650,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Lexeo Therapeutics during the fourth quarter worth approximately $47,299,000. Balyasny Asset Management L.P. acquired a new stake in Lexeo Therapeutics in the second quarter valued at $16,117,000. State Street Corp boosted its stake in Lexeo Therapeutics by 485.1% during the 4th quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after acquiring an additional 2,642,877 shares during the last quarter. Finally, Orbimed Advisors LLC bought a new position in shares of Lexeo Therapeutics during the fourth quarter worth about $21,101,000. Institutional investors and hedge funds own 60.67% of the company’s stock.

Wall Street Analyst Weigh In

LXEO has been the subject of several research analyst reports. HC Wainwright cut their price target on Lexeo Therapeutics from $13.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, January 13th. Weiss Ratings cut Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Chardan Capital reissued a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research report on Tuesday, January 13th. Finally, Wall Street Zen cut shares of Lexeo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 2nd. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $18.88.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.